Format

Send to

Choose Destination
Oncoimmunology. 2017 Aug 14;6(11):e1358330. doi: 10.1080/2162402X.2017.1358330. eCollection 2017.

mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer.

Author information

1
Department of Genetic, Institut curie, Unité de pharmacogénomique, Service de génétique, Paris, France.
2
Department of Urology, Institut Paoli-Calmettes, Service d'Urologie, Marseille, France.
3
Department of Pathology, Université Paris Descartes; Hôpital Cochin, Service d'Anatomopathologie, Paris, France.
4
Department of Urology, Université Paris Descartes, Hôpital Cochin, Service d'Urologie, Paris, France.
5
Department of Translational Immunotherapy, Institut Curie, PSL Research University, INSERM U932, Translational Immunotherapy Siric Team, Centre d'Investigation Clinique Biothérapie CICBT , Paris, France.
6
Centre de Recherche des Cordeliers, Cancer et Immunité anti tumorale, INSERM U1138, Paris, France.
7
Université Paris Descartes, Paris, France.

Abstract

Immunotherapy for bladder cancer has given promising results. Here we aimed to evaluate the possible involvement and prognostic value of 33 genes involved in the immune response during bladder carcinogenesis. Expression levels were assessed by quantitative real-time RT-PCR in normal and tumor human bladder samples. Immunohistochemistry was performed to evaluate the protein expression of 2 genes and relation of the mRNA and protein levels was analyzed. Tumors were obtained from 154 patients (83 with muscle-invasive bladder cancer [MIBC] and 71 non-MIBC [NMIBC]) who underwent transurethral bladder resection or radical cystectomy between 2002 and 2006. All patients signed an informed consent. Results of molecular analyses were coupled with survival analyses. Overall, 25 genes (75.8%) were significantly overexpressed in MIBC and 15 (45.5%) were deregulated in NMIBC as compared with normal tissue. On multivariate analysis, risk of NMIBC recurrence was increased with high FOXP3/CD8 ratio and overexpression of OX40L (p = 0.016 and p = 0.0039, respectively). In MIBC, a molecular signature of 3 genes (OX40L, CD8 and TIGIT) was significantly associated with prognosis in terms of recurrence-free and overall survival (p = 0.0007 and p = 0.007). RT-PCR findings were confirmed by immunohistochemistry for CD8 and FOXP3, with high association between mRNA and protein levels. Finally, risk of recurrence of non-muscle-invasive bladder cancer was increased with high FOXP3/CD8 ratio and OX40L overexpression. We identified a 3 gene molecular signature associated with prognosis of muscle-invasive bladder cancer. These results confirm the useful role of immune checkpoints in bladder carcinogenesis and suggest targets for therapy.

KEYWORDS:

Bladder cancer; RT-PCR; immune checkpoints; immunohistochemistry; prognostic factor

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center